login
Password reminder
Cardiac Rhythm News
Contact the editor Visit Cardiac Rhythm News Twitter feed Visit Cardiac Rhythm News Facebook page
 

FDA and industry reach agreement in principle on medical device user fees


Tuesday, 21 Feb 2012 16:14

The FDA and representatives from the medical device industry have reached an agreement in principle on proposed recommendations for the third reauthorisation of a medical device user fee programme.


The recommendations would authorise the FDA to collect US$595 million in user fees over five years, plus adjustments for inflation. Details of the agreement, such as the fee structure, are expected to be finalised soon.


Under a user fee programme, industry agrees to pay fees to help fund a portion of the FDA’s device review activities while the FDA agrees to overall performance goals such as reviewing a certain percentage of applications within a particular time frame.


The agreement in principle is the result of over a year of negotiations between the FDA and industry. It strikes a careful balance between what industry agreed to pay and what the FDA can accomplish with the amount of funding proposed. It would result in greater accountability, predictability, and transparency through such improvements as a more structured pre-submission process and earlier interactions between FDA and applicants. With the additional funding, the FDA would be able to hire over 200 full-time equivalent workers by the end of the five-year programme. The FDA and industry expect that the agreement in principle would result in a reduction in average total review times.


“I want to commend my staff and representatives from industry for their tireless work and commitment to achieving an agreement in principle on medical device user fees,” said FDA commissioner Margaret A Hamburg. “Reauthorisation of this important programme is an essential component for advancing medical device innovation.”


The industry associations who have reached an agreement in principle with the FDA include the Advanced Medical Technology Association, the Medical Device Manufacturers Association and the Medical Imaging and Technology Alliance.

Congress first established the user fee programme 10 years ago with the Medical Device User Fee and Modernization Act of 2002 (MDUFA I), prompted by growing concerns about the capacity and performance of the medical device review programme. The five-year programme was reauthorised with the Medical Device User Fee Act of 2007 (MDUFA II) and is set to expire on 30 September.


MDUFA II authorised FDA to collect user fees for certain medical device applications, for the registration of certain medical device establishments, and for certain other purposes. Small businesses may qualify for a waiver from fees on certain submissions or may qualify for a reduced fee.


In September 2010, prior to beginning negotiations with regulated industry, the FDA held a public meeting on the device user fee programme attended by a variety of stakeholders including industry, scientific and academic experts, health care professionals, and representatives from patient and consumer advocacy groups. Stakeholders provided their assessment of the overall performance of the MDUFA programme and their opinions about which aspects of the programme should be retained, changed, or discontinued in order to further strengthen and improve the programme.


Once the final details of the agreement with industry is completed, FDA will develop a package of proposed recommendations and give the public an opportunity to comment before they are submitted to Congress.


The date of the public meeting has yet to be determined.




Add New Comment

Most popular


New ultrasound-based system shows promise mapping atrial fibrillation
Wednesday, 06 Jan 2016
Initial findings have shown that a new ultrasound-based imaging system with continuous dipole density mapping provides real-time rapid global left atrial reconstruction and compares favourably to ... New ultrasound-based system shows promise mapping atrial fibrillation

Implantation of multiple leadless pacemakers is feasible without impacting cardiac function
Friday, 05 Feb 2016
An animal study from China has indicated that it is feasible to implant two leadless pacemakers in the right ventricle of the same heart without impacting cardiac function at six months. Implantation of multiple leadless pacemakers is feasible without impacting cardiac function

Abbott acquires Kalila Medical
Wednesday, 03 Feb 2016
Kalila Medical has a novel steerable sheath that is designed to help physicians more easily access and perform catheter-based electrophysiology procedures. Abbott acquires Kalila Medical

Features


Has leadless pacing changed practice?
Monday, 18 Jan 2016
Chu-Pak Lau explores the development and use of externally-powered and entirely intracardiac leadless pacemakers, and considers the effect they have had on clinical practice. Has leadless pacing changed practice?

In the absence of testing, ICD optimisation should always be done
Friday, 08 Jan 2016
Mark W Kroll (Minneapolis, USA) writes about the importance of optimisation of implantable cardioverter defibrillators (ICDs) in the absence of defibrillation threshold testing. In the absence of testing, ICD optimisation should always be done

Profiles


Jonathan Kalman
Monday, 18 Jan 2016
A leading heart rhythm expert in Australia, Jonathan M Kalman directs both clinical and research ... Jonathan Kalman

Michael Glikson
Wednesday, 14 Oct 2015
Michael Glikson (Tel Hashomer, Israel) has contributed to the development of technologies for CRT, ... Michael Glikson

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions